I would think after the GMU in vitro results, the
Post# of 72440
There are billions of dollars to be made with a robust therapeutic, and I doubt any C suite officers will be slow to make offers if Brilacidin shows it's therapeutic power.
Right now Leo's hard at work on the annual K filing, but I'll bet some news drops before the end of month, even if it's only the data lock.
Exciting times ahead!